Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 16, 2022

CBN is a popular cannabinoid, but what should we know about CBN and sleep? This minor cannabinoid has always existed in the cannabis plant in small quantities, but it is gaining in popularity for its potential healing properties. Unlike some other cannabinoids, it is not present in substantial amounts in fresh cannabis flower.

Sleep 94

Sleep Cannabinoids THC CBD 94

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.

CBD 295

CBD Clinical Trials Data Treatment 295

NORML

APRIL 30, 2020

According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy.

Chronic Pain 341

Chronic Pain Clinical Trials Data Patients 341

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

AUGUST 28, 2022

Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.

Cannabinoids 52

Cannabinoids Trichome Treatment Clinical Trials 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

The Joint Blog

NOVEMBER 8, 2020

We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients, and we suggest that this therapy could be included as an herbal medicine option for the treatment of this condition in the Brazilian public health system.”. mg/mL of THC and 0.51

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

LifeCannMD

FEBRUARY 27, 2024

Medical Marijuana exhibits neuroprotective properties, meaning it can protect nerve cells against damage, degeneration, or impairment of function in conditions like epilepsy, where excessive neuronal activity can lead to damage. CBD’s ability to reduce glutamate levels and enhance GABA activity can help to reduce seizures.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

AUGUST 19, 2021

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Britain has experienced a “quiet cannabis revolution” that has transformed it into “the world’s second largest consumer cannabinoids market”, ACI said.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 193

Clinical Trials Chronic Pain Data Treatment 193

Cannabis Law Report

DECEMBER 21, 2021

They concluded that CBG should be evaluated for clinical trials in individuals with IBD. Researchers used an experimental paradigm to investigate CBG and other cannabinoids’ potential neuroprotective properties in mice. CBG was discovered to lower inflammation and nitric oxide production.

Conditions 52

Conditions Research and Development Clinical Trials Oil 52

Cannabis Law Report

AUGUST 13, 2021

Instead, it is hypothesised that SalA indirectly influences the cannabinoid system, as well as being an allosteric modulator of the µ opioid receptor. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Canna Care Docs

OCTOBER 3, 2023

Alleviating Symptoms with Cannabinoids As more states legalize medical cannabis, many researchers and clinicians are studying the efficacy of cannabinoids like THC and CBD for alleviating these symptoms. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? Glaucoma: Understanding the Condition Understanding glaucoma is crucial for recognizing its symptoms and seeking timely treatment.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

LifeCannMD

FEBRUARY 27, 2024

How Medical Marijuana Is Changing Lives with Crohn’s Disease Medical Marijuana is a great treatment option for battling Crohn’s Disease, a chronic inflammatory bowel condition that affects millions worldwide. Some clinical trials have focused on the anti-inflammatory effects of cannabis in Crohn’s disease.

Marijuana 59

Marijuana Clinical Trials Treatment Therapy 59

United Patients Group

JANUARY 8, 2023

Cannabis has been shown to be an effective treatment for a variety of conditions caused by bacteria, viruses and fungi. This is because it contains cannabinoids, which have anti-inflammatory properties. Many neurological conditions are associated with dysregulation of the ECS (for example: epilepsy, Parkinson’s disease).

Blood Pressure 105

Blood Pressure Sleep Cannabinoids Clinical Trials 105

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

PrestoDoctor

SEPTEMBER 15, 2023

Obsessive-Compulsive Disorder (OCD) is a debilitating mental health condition that is characterized by intrusive thoughts and compulsive behaviors. Understanding OCD Obsessive-Compulsive Disorder (OCD) is a mental health condition that affects millions of individuals worldwide. These obsessions can vary greatly from person to person.

Research and Development 105

Research and Development Therapy Treatment Strains 105

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

MAY 10, 2022

Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

FloridaMarijuana.net

AUGUST 15, 2018

Additionally, the ACPA reported on a clinical trial that suggests that inhaled cannabis may provide short-term relief from Neuropathy. The endocannabinoid system consists of cannabinoid receptors all over the body. These damaged nerve fibers send incorrect signals to other pain centers. Analgesic/”Opiate Type Pain Relief”.

Chronic Pain 150

Chronic Pain Marijuana Patients Clinical Trials 150

FloridaMarijuana.net

JUNE 13, 2018

Additionally, the NCI recognizes that cannabinoids “may have benefits in the treatment of cancer-related side effects.”. Cannabinoids are extracted from the cannabis plant and an extract oil is created. It is important to speak with a medical marijuana physician to determine which method will work best with your medical condition.

Clinical Trials 189

Clinical Trials Marijuana Patients Chronic Pain 189

Veriheal

MAY 3, 2022

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep?

Sleep 133

Sleep Data Tincture Research and Development 133

The Cannigma

FEBRUARY 2, 2021

Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

OCTOBER 13, 2020

Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .

Digestion 123

Digestion Treatment Conditions Research and Development 123

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

CannaMD

MAY 12, 2021

It’s well known that marijuana can be an agent for appetite stimulation, making it a valuable therapy for mitigating the weight loss sometimes associated with conditions such as HIV/AIDS and cancer. The condition can lead to weight gain and obesity. Binges are often followed by feelings of guilt and shame.

Marijuana 119

Marijuana Therapy Conditions Food 119

CannaMD

MAY 25, 2021

In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. THC, CBD & THE ECS. THC, CBD & THE ECS. In their summary, the study’s authors noted that. MARIJUANA AND OSTEOPOROSIS.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111